强化csDMARD联合方案对比TNF抑制剂治疗活动性类风湿关节炎的成本效果
该务实随机多中心非劣效试验纳入205例对甲氨蝶呤和另一种DMARD应答不佳的活动性RA患者,比较强化csDMARD联合方案与TNFi的成本效果。csDMARD组各视角总成本显著更低,12个月HAQ评分显示csDMARD组获益,其他结局无差异。结论为起始强化csDMARD联合方案可获得相似结局且成本显著更低。
要点
- 对甲氨蝶呤和另一种DMARD应答不佳的活动性RA患者,起始强化csDMARD联合方案与TNFi相比结局相似。
- csDMARD组各视角总成本显著低于TNFi组,6个月和12个月健康与社会照护调整后均值差分别为-£3,615和-£1,930。
- csDMARD组6个月应答不佳者可换用TNFi,44%的患者转换。
核心结论
- 起始强化csDMARD联合方案而非TNFi可在显著更低成本下获得相似结局。
研究设计与样本
- 开放标签、12个月、务实、随机、多中心、双臂、非劣效试验,在英格兰和威尔士24家风湿科诊所开展。
- 共纳入205例活动性RA患者,csDMARD组104例,TNFi组101例。
- 采用试验内成本效果和成本效用分析,涵盖健康与社会照护视角及2种社会视角。
主要发现
- csDMARD组各视角总成本显著更低:6个月健康与社会照护调整后均值差-£3,615(95%CI -4,104, -3,182);12个月调整后均值差-£1,930(95%CI -2,599, -1,301)。
- 12个月HAQ评分显示csDMARD组获益(-0.16,95%CI -0.32, -0.01),其他结局/随访点无差异。
- csDMARD组6个月应答不佳者中46例(44%)换用TNFi。
- 6个月随访时93%参与者、12个月随访时91-92%参与者有相关成本与结局数据。
关键数值与推荐
- 对甲氨蝶呤和另一种DMARD应答不佳的活动性RA患者,符合NICE昂贵生物制剂标准者可接受强化csDMARD联合方案治疗,具有成本效果。
临床怎么用
- 对符合NICE昂贵生物制剂标准的活动性RA患者,可优先起始强化csDMARD联合方案,以成本效果方式治疗。
- 6个月应答不佳时可换用TNFi。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether intensive combinations of conventional synthetic disease-modifying antirheumatic drugs (csDMARDS) achieve similar clinical benefits more cheaply than high-cost biologics such as tumor necrosis factor inhibitors (TNFi) in patients with active rheumatoid arthritis (RA) whose illness has failed to respond to methotrexate and another DMARD. METHODS: We used within-trial cost-effectiveness and cost-utility analyses from health and social care and 2 societal perspectives. Participants were recruited into an open-label, 12-month, pragmatic, randomized, multicenter, 2-arm, noninferiority trial in 24 rheumatology clinics in England and Wales. Costs were linked with the Health Assessment Questionnaire (HAQ; primary outcome) and quality-adjusted life years derived from 2 measures (Short-Form 36 health survey and EuroQol 5-domain 3-level instrument). RESULTS: In total, 205 participants were recruited, 104 in the csDMARD arm and 101 in the TNFi arm. Participants in the csDMARD arm with poor response at 6 months were offered TNFi; 46 participants (44%) switched. Relevant cost and outcome data were available for 93% of participants at 6-month follow-up and for 91-92% of participants at 12-month follow-up. The csDMARD arm had significantly lower total costs from all perspectives (6-month health and social care adjusted mean difference -£3,615 [95% confidence interval (95% CI) -4,104, -3,182]; 12-month health and social care adjusted mean difference -£1,930 [95% CI -2,599, -1,301]). The HAQ score showed benefit to the csDMARD arm at 12 months (-0.16 [95% CI -0.32, -0.01]); other outcomes/follow-ups showed no differences. CONCLUSION: Starting treatment with csDMARDs, rather than TNFi, achieves similar outcomes at significantly lower costs. Patients with active RA and who meet the National Institute for Health and Care Excellence criteria for expensive biologics can be treated with combinations of intensive csDMARDs in a cost-effective manner.
引用
- Patel A, Heslin M, Scott DL, et al. Cost-Effectiveness of Combination Disease-Modifying Antirheumatic Drugs Versus Tumor Necrosis Factor Inhibitors in Active Rheumatoid Arthritis: A Pragmatic, Randomized, Multicenter Trial. Arthritis Care Res (Hoboken). 2020. PMID: 30629813. doi:10.1002/acr.23830
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。